Pharmaceutical News

RSS

Roundup: Md. Blues chief pans hospital costs shift plan; Pharmacies struggle with new drug controls

Negotiations to avert a breakdown in Maryland's unique system of regulating hospital prices have deteriorated into a stalemate between the state's largest insurer and the Maryland Hospital Association. CareFirst BlueCross BlueShield CEO Chet Burrell, speaking out for the first time about the talks, blames hospitals for their proposal to shift hundreds of millions in costs to CareFirst and other private insurers in an attempt to control rising Medicare spending.

28 Sep 2012

Story describes need for male version of oral contraceptive pills

When will men have their own birth control pill? Scientists have been predicting the debut of a male pill within 5 years for the last 30 years. The factors accounting for that delay - and new optimism that a male pill will emerge within a decade - are the topic of a story in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

27 Sep 2012

Aeterna Zentari expects to file AEZS-130 NDA with FDA for adult growth hormone deficiency

Aeterna Zentaris Inc. today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted.

27 Sep 2012

Study indicates the amounts paid by antipsychotic manufacturers to D.C. Medicaid psychiatrists

The D.C. Department of Health (DOH) has released a study by George Washington University School of Public Health & Health Services (SPHHS) indicating the high levels of marketing by antipsychotic drug manufacturers to Medicaid psychiatrists in the District of Columbia.

27 Sep 2012

Key bacterial protein structures reveal one of the biochemical secrets behind multi-drug tolerance

The structures of key bacterial proteins have revealed one of the biochemical secrets that enables bacteria to outwit antibiotics.

27 Sep 2012

Anxiety, depression and insomnia drugs and risk of driving accident: an interview with Hui-Ju Tsai

Anxiety, depression and insomnia drugs have been commonly used to treat mental and emotional disorders, or improve sleep-related problems.

27 Sep 2012

Eaton highlights potential of Tropine 3 for women with hot flashes

Eaton Scientific Systems, Ltd. a wholly-owned subsidiary of Pristine Solutions, Inc. is pleased to highlight the increasing international potential of Tropine 3 for the non-hormonal treatment for pre-menopausal, peri-menopausal, and post-menopausal women experiencing hot flashes.

27 Sep 2012

Challenges to India's role as global pharmaceutical supplier

"India has had a positive global impact through its supply of vast quantities of low-cost, good-quality generic medicines, which have saved or prolonged millions of lives ... but there are also many factors that may hinder the continuation of the country's role as chief supplier of medicines to developing countries," Martin Khor, executive director of the South Centre in Geneva, writes in an Inter Press Service opinion piece.

27 Sep 2012

Combination of two neuroprotective therapies shows promise against Alzheimer's

The combination of two neuroprotective therapies, voluntary physical exercise, and the daily intake of melatonin has been shown to have a synergistic effect against brain deterioration in rodents with three different mutations of Alzheimer's disease.

27 Sep 2012

Study sheds new light on potential habit-forming properties of tramadol

A study by a team of University of Kentucky researchers has shed new light on the potential habit-forming properties of the popular pain medication tramadol, in research funded by the National Institute on Drug Abuse.

27 Sep 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Dr. Reddy's introduces generic Singulair oral granules in the U.S.

Dr. Reddy's Laboratories announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair (montelukast sodium) oral granules in the US market on September, 26, 2012, following the approval by the United States Food & Drug Administration (USFDA) of Dr.Reddy's ANDA for Montelukast Sodium Oral Granules.

27 Sep 2012

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

27 Sep 2012

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."

27 Sep 2012

Alitair receives U.S. patent allowance for ion exchange resin formulation of benzonatate

Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate.

27 Sep 2012

Adult stem cells can prevent Alzheimer's disease

In the first study of its kind, researchers at Korea's leading university and the RNL Bio Stem Cell Technology Institute announced this week the results of a study that suggests an astounding possibility: adult stem cells may not only have a positive effect on those suffering from Alzheimer's disease, they can prevent the disease.

27 Sep 2012

Pharmaceutical News

Roundup: Md. Blues chief pans hospital costs shift plan; Pharmacies struggle with new drug controls

Story describes need for male version of oral contraceptive pills

Aeterna Zentari expects to file AEZS-130 NDA with FDA for adult growth hormone deficiency

Study indicates the amounts paid by antipsychotic manufacturers to D.C. Medicaid psychiatrists

Key bacterial protein structures reveal one of the biochemical secrets behind multi-drug tolerance

Anxiety, depression and insomnia drugs and risk of driving accident: an interview with Hui-Ju Tsai

Eaton highlights potential of Tropine 3 for women with hot flashes

Challenges to India's role as global pharmaceutical supplier

Combination of two neuroprotective therapies shows promise against Alzheimer's

Study sheds new light on potential habit-forming properties of tramadol

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Dr. Reddy's introduces generic Singulair oral granules in the U.S.

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Alitair receives U.S. patent allowance for ion exchange resin formulation of benzonatate

Adult stem cells can prevent Alzheimer's disease

CSL develops new drug candidate against type 2 diabetes

Tips on safe use of opioids in hospitals

American Society of Anesthesiologists announces partnership with The Medicine Abuse Project

Double-digit premium increases seen in popular Medicare drug plans

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News